Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

HINJ, PhRMA, Others Challenge NJ Attorney General’s Push to Limit Compensation to Prescribing Doctors

Dean J. Paranicas, President and Chief Executive Officer, HINJ

Trenton, NJ, October 23, 2017 — WHYY Public Radio Philadelphia’s Joe Hernandez reports that, in a new push to fight the opioid crisis, New Jersey officials are trying to stop the flow of legal but highly addictive painkillers at the source: doctors.

A proposed rule change by N.J. Attorney General Christopher Porrino would restrict the amount of money and other compensation drug companies can give out to doctors and other prescribers.  In doing so, state officials hope medical professionals will feel less pressure to prescribe opioids created and sold by the same companies that ply them with gifts and food.

But at a Thursday public hearing in Newark, representatives of the state’s pharmaceutical and medical industries criticized the potential rule change, questioning why it would apply to all drugs and claiming it would damage patient care and drive providers out of state.

“That’s not a good result for patients, for our state’s life sciences community, for health care professionals, or for New Jersey’s economy,” said Dean Paranicas, president of the HealthCare Institute of New Jersey (HINJ), which represents biopharmaceutical and medical technology companies.

Paranicas and others also predicted that the new restrictions would make it harder for pharmaceutical companies to hire doctors to run clinical trials, forcing that industry to shift to other markets, too.

Potential Changes

Porrino’s proposal is two-pronged. First, it would set limits on how much doctors and other medical professionals could be paid for certain work or be given in the form of meals.

An individual prescriber would be allowed to accept only $10,000 per year for “bona fide services,” which include speaking engagements, sitting on advisory boards, and consulting. Prescribers could accept just four free meals annually valued at $15 or less.

The proposal would also ban prescribers entirely from accepting certain gifts from drug companies that may have been permitted in the past — such as cash, entertainment, and gift cards.

There are exceptions to the rule. There would be no limit on free materials directly benefiting patients, such as medication samples and anatomical models used in exam rooms. Doctors could also exceed the $10,000 cap for speaking at continuing-education classes.

“We want doctors in New Jersey to make prescribing decisions based only on what’s in the best interest of their patients,” said Porrino, in an interview, “not based on meals that may be provided or compensation that might be provided by pharma companies.”

The amount of money at issue is not insignificant. In 2016 alone, New Jersey doctors received $69 million from drug and device manufacturers, according to the attorney general’s office.

Second Opinions

Much of the testimony during Thursday’s public hearing, largely by representatives of the state’s biopharmaceutical and medical research industries, opposed the plan. Yet most speakers praised Porrino and the Christie administration for trying to beat back the opioid crisis.

Among the criticisms of the proposal: companies selling drugs other than opioids would be included; doctors would be restricted from participating in clinical trials; physicians would not be able to report back to drugmakers about how medications are working on their patients; and researchers would abandon New Jersey for other states.

“Overall, I think the proposal is well intentioned but too broad in its application,” said Larry Downs, CEO of the Medical Society of New Jersey, which represents doctors.

Downs lauded the administration’s goal of limiting the influence of drugmakers on medical decision making, but predicted that the rule would impede doctors from participating in trials, consultancies and events genuinely aimed at improving patient care.

“We would ask that a much narrower rule be proposed that would really get at the sources of real influence, like out-and-out gifts,” he said.

For Hernandez’ full story, click here.

Follow Joe Hernandez on Twitter @byjoehernandez.